Exchange Traded Concepts LLC Has $1.86 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Exchange Traded Concepts LLC cut its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 16.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 62,426 shares of the specialty pharmaceutical company's stock after selling 12,669 shares during the quarter. Exchange Traded Concepts LLC owned 0.19% of Collegium Pharmaceutical worth $1,863,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Rhumbline Advisers grew its holdings in shares of Collegium Pharmaceutical by 5.8% during the 4th quarter. Rhumbline Advisers now owns 108,228 shares of the specialty pharmaceutical company's stock worth $3,101,000 after purchasing an additional 5,920 shares in the last quarter. Sanctuary Advisors LLC grew its holdings in shares of Collegium Pharmaceutical by 5.3% during the 4th quarter. Sanctuary Advisors LLC now owns 18,928 shares of the specialty pharmaceutical company's stock worth $542,000 after purchasing an additional 952 shares in the last quarter. Versor Investments LP boosted its stake in Collegium Pharmaceutical by 36.2% during the fourth quarter. Versor Investments LP now owns 19,582 shares of the specialty pharmaceutical company's stock worth $561,000 after buying an additional 5,200 shares in the last quarter. Aigen Investment Management LP acquired a new stake in Collegium Pharmaceutical during the fourth quarter worth $230,000. Finally, Raymond James Financial Inc. acquired a new stake in Collegium Pharmaceutical during the fourth quarter worth $2,432,000.

Collegium Pharmaceutical Price Performance

NASDAQ:COLL traded up $0.23 on Friday, reaching $29.83. The stock had a trading volume of 669,952 shares, compared to its average volume of 405,163. The company has a market capitalization of $958.44 million, a P/E ratio of 24.45 and a beta of 0.63. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $42.29. The company has a quick ratio of 1.01, a current ratio of 1.08 and a debt-to-equity ratio of 3.30. The stock has a fifty day moving average price of $28.57 and a 200-day moving average price of $29.52.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing the consensus estimate of $1.50 by ($0.01). The business had revenue of $177.76 million during the quarter, compared to analyst estimates of $174.96 million. Collegium Pharmaceutical had a return on equity of 99.08% and a net margin of 6.61%. The firm's revenue was up 22.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.45 earnings per share. Research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, Director John Gordon Freund sold 6,601 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $30.62, for a total transaction of $202,122.62. Following the transaction, the director now owns 70,658 shares of the company's stock, valued at approximately $2,163,547.96. This represents a 8.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.51% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on COLL shares. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Piper Sandler reiterated a "neutral" rating and set a $37.00 target price (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Needham & Company LLC reaffirmed a "buy" rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $43.75.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.